Johanson J F
Department of Medicine, University of Illinois College of Medicine, Rockford, IL, USA.
Neurogastroenterol Motil. 2004 Dec;16(6):701-11. doi: 10.1111/j.1365-2982.2004.00550.x.
This article reviews the efficacy and tolerability of traditional therapies for irritable bowel syndrome (IBS) and concludes that they are limited by both poor efficacy and adverse effects. Serotonin, a neurotransmitter found mainly in the gut, appears to represent a link in IBS pathophysiological processes -- altered gut motility, abnormal intestinal secretion and visceral hypersensitivity. Recently, available treatments for IBS have targeted serotonin receptors that are involved in motor, sensory and secretory functions of the gut. Serotonergic agents, such as alosetron (a 5-HT3 receptor antagonist) and tegaserod (a selective 5-HT4 receptor partial agonist), provide global relief of the multiple symptoms of IBS with diarrhoea and IBS with constipation, respectively, and represent important additions to the IBS treatment armamentarium.
本文综述了肠易激综合征（IBS）传统疗法的疗效和耐受性，并得出结论：这些疗法因疗效不佳和不良反应而受到限制。血清素是一种主要存在于肠道中的神经递质，似乎是肠易激综合征病理生理过程（肠道蠕动改变、肠道分泌异常和内脏超敏反应）中的一个环节。最近，针对肠易激综合征的现有治疗方法靶向参与肠道运动、感觉和分泌功能的血清素受体。血清素能药物，如阿洛司琼（一种5-HT3受体拮抗剂）和替加色罗（一种选择性5-HT4受体部分激动剂），分别为腹泻型肠易激综合征和便秘型肠易激综合征的多种症状提供全面缓解，是肠易激综合征治疗手段的重要补充。
